Intech Investment Management LLC Grows Stake in BioLife Solutions, Inc. (NASDAQ:BLFS)

Intech Investment Management LLC lifted its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 164.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,985 shares of the medical equipment provider’s stock after purchasing an additional 16,785 shares during the quarter. Intech Investment Management LLC owned about 0.06% of BioLife Solutions worth $701,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. State Street Corp grew its position in BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after buying an additional 95,788 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of BioLife Solutions by 2.2% during the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after purchasing an additional 18,473 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of BioLife Solutions in the fourth quarter worth approximately $20,664,000. Rockefeller Capital Management L.P. raised its stake in BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after purchasing an additional 262,504 shares in the last quarter. Finally, Mutual of America Capital Management LLC lifted its position in BioLife Solutions by 31.2% during the fourth quarter. Mutual of America Capital Management LLC now owns 521,937 shares of the medical equipment provider’s stock valued at $13,549,000 after purchasing an additional 124,165 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

BLFS has been the topic of a number of research analyst reports. Benchmark reissued a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. HC Wainwright raised their price target on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. StockNews.com raised BioLife Solutions from a “sell” rating to a “hold” rating in a research note on Wednesday, March 19th. Northland Securities increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Finally, KeyCorp boosted their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.86.

Insider Buying and Selling

In other news, CFO Troy Wichterman sold 987 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sarah Aebersold sold 5,632 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $24.96, for a total value of $140,574.72. Following the transaction, the insider now owns 45,860 shares in the company, valued at approximately $1,144,665.60. This represents a 10.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,117 shares of company stock valued at $534,442 over the last three months. 2.20% of the stock is owned by company insiders.

BioLife Solutions Stock Down 0.3 %

BLFS opened at $24.99 on Monday. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The business’s 50-day moving average price is $26.40 and its 200-day moving average price is $25.49. The company has a market cap of $1.17 billion, a P/E ratio of -23.58 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The business had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the previous year, the firm earned ($0.21) EPS. On average, equities analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.